2-[3-(1,3,4-Thiadiazol-2-yl)propyl]-1,3,4-thiadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-(1,3,4-Thiadiazol-2-yl)propyl]-1,3,4-thiadiazole
• 英文别名: 2-[3-(1,3,4-thiadiazol-2-yl)propyl]-1,3,4-thiadiazole
• 化学式: C₇H₈N₄S₂
• 分子量: 212.3
• InChiKey: DTNDVAJCUWQPPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• COMPOUNDS AND THEIR METHODS OF USE
  申请人：Lemieux Rene M.

  公开号：US20140142081A1

  公开（公告）日：2014-05-22

  Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

  本文描述了含有抑制谷氨酸酶的化合物和组合物。本文还描述了利用这些抑制谷氨酸酶的化合物治疗癌症的方法。
• METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS
  申请人：Calithera Biosciences, Inc.

  公开号：US20160287564A1

  公开（公告）日：2016-10-06

  In some aspects, the invention relates to a method of treating cancer, a myeloproliferative disease, an immunological disease, a neurological disease, or a viral infection, comprising orally administering a compound of formula I, formula II, formula III, formula IV, formula V, and/or formula VI, wherein the compound is administered with a meal (e.g., with food as defined herein) or in fed mode.
• Treatment of Lung Cancer with Inhibitors of Glutaminase
  申请人：Calithera Biosciences, Inc.

  公开号：US20160287585A1

  公开（公告）日：2016-10-06

  The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.
• TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE
  申请人：Liang Yu

  公开号：US20180055825A1

  公开（公告）日：2018-03-01

  The invention relates to method of treating a disease or disorder (e.g., such as cancer) in a subject, comprising administering to the subject heterocyclic compounds and pharmaceutical preparations described herein, if the subject is determined to possess at least one G allele at single nucleotide polymorphism (SNP) rs6983267.
• Combination Therapy with Glutaminase Inhibitors
  申请人：Bennett Mark K.

  公开号：US20180055842A1

  公开（公告）日：2018-03-01

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.